The FDA issued an Emergency Use Authorization to a clinical decision support (CDS) tool that predicts when hospitalized COVID patients are at risk of further complications. Developed by Dascena, an Oakland, California-based diagnostic algorithm developer, the COViage Hemodynamic Instability and Respiratory Decompensation Prediction System reviews demographic and vital-sign data stored in a patients’ EHR, including age, sex, heart rate, respiratory rate, temperature and blood pressure. The CDS system uses machine learning models to calculate the patient’s risk of experiencing unstable blood pressure or respiratory failure. Read more here.
You are here: / / Dascena’s COViage Receives Emergency Use Authorization from FDA